"We are delighted to have Roger join Intec's Board at this pivotal time in the Company's evolution. His counsel on a range of strategic issues will be instrumental as we near the completion of our Phase 3 ACCORDANCE clinical trial of AP-Carbidopa/Levodopa (AP-CD/LD) to treat Parkinson's Disease, advance our pre-commercial activities and accelerate the continued development of our innovative Accordion Pill drug delivery solution in a variety of new indications," stated John W. Kozarich, Ph.D., Chairman of the Board of Intec Pharma. "Roger's considerable board experience will be of great value as we seek to expand our clinical development pipeline and advance collaborations and partnership opportunities with our proprietary Accordion Pill technology.""This is a very exciting time to be joining Intec's board as the Company is finalizing late stage testing of its Parkinson's Disease therapeutic and is leveraging its Accordion Pill platform to bring enhanced treatment options to patients across a broad spectrum of therapeutic areas," said Dr. Pomerantz. "I'm delighted to offer my insights and work with this Board as Intec drives long-term value creation and moves towards approval, launch and commercialization of its first product." About Intec Pharma Ltd. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various indications including low back neuropathic pain and fibromyalgia.
For more information, visit http://www.intecpharma.com.Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about the Company's expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company's control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company's filings with the Securities and Exchange Commission, and include the following: the company's ability to develop and commercialize its product candidates and obtain additional financing necessary therefor; the length, cost and uncertain results of the company's clinical trials; including uncertainty regarding the Company's ability to enroll the required number of patients therein; the potential of adverse side effects, other safety risks, or legal prohibitions on the use of certain products in certain jurisdictions that could preclude the approval of the company's drug candidates; the availability of reimbursement from government authorities and health insurance companies for the company's products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.
Intec Pharma Investor Contact: Bob YedidLifeSci Advisors(646)-597-6989 firstname.lastname@example.orgSOURCE Intec Pharma Ltd.